NASDAQ: KODKodiak Sciences Inc Stock
$3.19-0.19 (-5.62%)
Updated Apr 25, 2024
KOD Price
$3.19
Fair Value Price
$1.98
Market Cap
$167.24M
52 Week Low
$1.37
52 Week High
$9.80
P/E
-0.64x
P/B
0.63x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$260.49M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.8
Operating Cash Flow
-$154M
Beta
1.47
Next Earnings
Jun 4, 2024
Ex-Dividend
N/A
Next Dividend
N/A
KOD Overview
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how KOD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KOD ($3.19) is overvalued by 60.71% relative to our estimate of its Fair Value price of $1.98 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
KOD ($3.19) is not significantly undervalued (60.71%) relative to our estimate of its Fair Value price of $1.98 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
KOD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KOD due diligence checks available for Premium users.
Be the first to know about important KOD news, forecast changes, insider trades & much more!
KOD News
Valuation
KOD fair value
Fair Value of KOD stock based on Discounted Cash Flow (DCF)
Price
$3.19
Fair Value
$1.98
Overvalued by
60.96%
KOD ($3.19) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KOD ($3.19) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KOD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KOD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.64x
Industry
15.41x
Market
40.97x
KOD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.63x
Industry
5.8x
KOD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KOD's financial health
Profit margin
Revenue
$0.0
Net Income
-$59.5M
Profit Margin
0%
KOD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$479.4M
Liabilities
$213.6M
Debt to equity
0.8
KOD's short-term assets ($289.31M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KOD's short-term assets ($289.31M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KOD's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
KOD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$32.2M
Investing
-$27.8M
Financing
-$124.0k
KOD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KOD vs Biotech Stocks
Kodiak Sciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.